AR and prostate cancer: One previous study assessed advanced and metastatic prostate cancer genomic features, and found RB1 loss is significantly associated with poor prognosis, whereas RB1, AR, and TP53 alterations predict shorter PFS in patients with ongoing androgen signaling inhibitors.